Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA (TOCIAION)
Open Label Phase II Randomized Non-comparative Study of SC Tocilizumab Associated With IV Pulse Steroid Versus IV Pulse Steroid Alone for the Treatment of Acute Anterior Ischemic Optic Neuropathy Associated With Giant Cell Arteritis
Sponsor: Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
A PHASE2 clinical study on Giant Cell Arteritis and Optic Ischaemic Neuropathy, this trial is ongoing. The trial is conducted by Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts and has accumulated 10 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Apr 2024 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Apr 2022 — Apr 2024 [monthly]
Recruiting PHASE2
Status: Unknown Status → Recruiting
-
Jan 2022 — Apr 2022 [monthly]
Unknown Status PHASE2
Status: Not Yet Recruiting → Unknown Status
▶ Show 5 earlier versions
-
Jan 2021 — Jan 2022 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Jun 2020 — Jul 2020 [monthly]
Not Yet Recruiting PHASE2
-
May 2020 — Jun 2020 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2020 — May 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
- Roche Chugai
For direct contact, visit the study record on ClinicalTrials.gov .